Senores Pharmaceuticals IPO

About the company

Senores Pharmaceuticals Limited, established in 2017, is a research-driven company focused on developing and manufacturing a wide range of generic pharmaceutical products. The company operates through two key business models: Marketed products (ANDA products and sourced products) and contract development and manufacturing operations (CDMO). As of September 2024, Senores Pharmaceuticals has received approvals for 19 ANDA (Abbreviated New Drug Application) and has commercialised 21 products from these ANDA approvals. Some of the company’s products also have exclusivity periods in key markets, during which no other company can launch competing versions of the same product for six months.

Financial performance (₹ Cr)

Subscription breakup (final, times)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   20 Dec 2024

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   24 Dec 2024

   Last day to place your bid

3. Basis of Allotment

   Completed
   26 Dec 2024

   Share allotment finalised

4. Refund Initiation

   Completed
   27 Dec 2024

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   27 Dec 2024

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   30 Dec 2024

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.